试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-07-19
Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B
编号:NCT03778879登记状态:入组前撤回企业 / 申办者:Alan Katz
药物 / 成分:CCX872-B
登记的停止原因(原文):CCX872-B will not be available in sufficient quantity to conduct the study.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-07-19
Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD)
编号:NCT03855865登记状态:入组前撤回企业 / 申办者:Naurex, Inc, an affiliate of Allergan plc
药物 / 成分:Rapastinel、Vortioxetine、Placebo
登记的停止原因(原文):Business decision to stop the program.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-07-18
Polypharmacy-related Adverse Events in Critically Ill Children
编号:NCT03293927登记状态:入组前撤回企业 / 申办者:Duke University
药物 / 成分:Fentanyl、Dexmedetomidine
登记的停止原因(原文):No participants enrolled in study.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-07-18
The Efficacy of Brisement Compared to Physical Therapy for the Treatment of Achilles Tendinosis
编号:NCT03363789登记状态:入组前撤回企业 / 申办者:Brigham and Women's Hospital
药物 / 成分:Brisement injection、Physical Therapy
登记的停止原因(原文):Insufficient recruitment
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-07-18
Regional Anesthesia Block in Fibula Free Flap Reconstruction
编号:NCT03906838登记状态:入组前撤回企业 / 申办者:University of Florida
药物 / 成分:Ropivacaine injection
登记的停止原因(原文):funding not obtained
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-07-17
MicroRNA and MicroRNA Inhibitors Socket Study, Pilot Clinical Trial
编号:NCT02579187登记状态:入组前撤回企业 / 申办者:Gustavo Avila-Ortiz DDS, MS, PhD
药物 / 成分:tooth extraction、CBCT scan、Anesthesia、clinical measurements
登记的停止原因(原文):withdrawn study from IRB
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-07-17
Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft
编号:NCT03393273登记状态:入组前撤回企业 / 申办者:Assistance Publique - Hôpitaux de Paris
药物 / 成分:Elotuzumab
登记的停止原因(原文):Investigator decision in accordance with the promotor
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-07-17
Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Persistent Asthma
编号:NCT03834012登记状态:入组前撤回企业 / 申办者:Adamis Pharmaceuticals Corporation
药物 / 成分:Beclomethasone 800 µg per day、Placebo、Beclomethasone 400 µg per day、Beclomethasone 640 µg per day
登记的停止原因(原文):Sponsor Decision
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-07-17
Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Mild to Moderate Persistent Asthma
编号:NCT03835871登记状态:入组前撤回企业 / 申办者:Adamis Pharmaceuticals Corporation
药物 / 成分:Placebo、400 µg per day Beclomethasone、200 µg per day Beclomethasone、100 µg per day Beclomethasone
登记的停止原因(原文):Sponsor decision
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-07-15
RCT Comparing Standard Cannula Delivered FS, UGFS and ClariVein® in the Management of SVI
编号:NCT02010437登记状态:入组前撤回企业 / 申办者:Hull University Teaching Hospitals NHS Trust
药物 / 成分:Sodium Tetradecyl Sulphate (STS)
登记的停止原因(原文):Study design has been substantially revised and a new registration will be made in the future.
查看官方原始记录 ↗